J1

9lr3236 CF SB 820

### By: **Delegates Ciliberti, Cox, Krimm, McComas, McKay, and Pippy** Introduced and read first time: February 25, 2019 Assigned to: Rules and Executive Nominations

### A BILL ENTITLED

#### 1 AN ACT concerning

# Public Health - Co-Prescribing, Prescribing and Dispensing Opioid Overdose Reversal Drugs

- 4 FOR the purpose of requiring that certain guidelines for the co-prescribing of opioid  $\mathbf{5}$ overdose reversal drugs be consistent with certain requirements; authorizing the 6 Secretary of Health to post on the Maryland Department of Health's website certain 7 guidelines and clinical guidance; authorizing a prescribing licensed health care 8 provider to co-prescribe or prescribe or a pharmacist to dispense an opioid overdose 9 reversal drug to certain individuals under certain circumstances; requiring a 10 prescribing licensed health care provider to routinely assess a patient's risk of being 11 likely to experience or witness an opioid overdose; authorizing a prescribing licensed 12health care provider or a pharmacist to use certain information to determine a 13 patient's risk of being likely to experience or witness an opioid overdose; requiring a prescribing licensed health care provider or pharmacist to provide certain 1415information to certain patients on certain matters under certain circumstances; 16prohibiting a prescribing licensed health care provider and pharmacist from taking 17certain actions until the prescribing licensed health care provider or pharmacist 18 completes certain training; authorizing certain licensing boards to enforce this Act; 19requiring a prescribing licensed health care provider to document in a patient's 20medical record certain services provided; making conforming changes; altering a 21 certain definition; defining certain terms; and generally relating to co-prescribing, 22prescribing, and dispensing opioid overdose reversal drugs.
- 23 BY repealing and reenacting, with amendments,
- 24 Article Health General
- 25 Section 13–3501 and 13–3502
- 26 Annotated Code of Maryland
- 27 (2015 Replacement Volume and 2018 Supplement)

28 BY adding to

29 Article – Health – General

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW. [Brackets] indicate matter deleted from existing law.



 $\mathbf{2}$ 

1 Section 13-3503  $\mathbf{2}$ Annotated Code of Maryland (2015 Replacement Volume and 2018 Supplement) 3 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 4 That the Laws of Maryland read as follows:  $\mathbf{5}$ 6 Article – Health – General 7 13 - 3501.8 (a) In this subtitle the following words have the meanings indicated. 9 "Co-prescribing" means, with respect to an opioid overdose reversal drug, the (b)practice of prescribing the drug in conjunction with an opioid prescription for a patient at 10 an elevated risk of overdose. 11 12"MONITORED PRESCRIPTION DRUG" HAS THE MEANING STATED IN § (C) 21-2A-01 OF THIS ARTICLE. 1314[(c)] **(D)** "Opioid overdose reversal drug" means naloxone or [a similarly acting 15and equally safe] ANY OTHER drug that RAPIDLY REVERSES THE RESPIRATORY **DEPRESSANT EFFECTS OF AN OPIOID MEDICATION AND** is approved by the federal Food 16 17and Drug Administration for the treatment of a known or suspected opioid overdose. 18 **(E)** "PHARMACIST" MEANS AN INDIVIDUAL WHO IS AUTHORIZED BY LAW TO 19 **DISPENSE A MONITORED PRESCRIPTION DRUG.** 20**(F)** "PRESCRIBING LICENSED HEALTH CARE PROVIDER" MEANS AN INDIVIDUAL WHO IS AUTHORIZED BY LAW TO PRESCRIBE A MONITORED 2122PRESCRIPTION DRUG. 2313 - 3502.24(a) The Secretary shall establish guidelines for the co-prescribing AND 25**PRESCRIBING** of opioid overdose reversal drugs that are applicable to all licensed health 26care providers in the State who are authorized by law to prescribe a monitored prescription 27drug[, as defined in § 21–2A–01 of this article]. 28(b) The guidelines established under subsection (a) of this section shall address 29the co-prescribing of opioid overdose reversal drugs for patients who are: 30 At an elevated risk of overdose: and (1)31(i) Receiving opioid therapy for chronic pain; (2)

1

(ii) Receiving a prescription for benzodiazepines; or

 $\mathbf{2}$ 

(iii) Being treated for opioid use disorders.

3 (C) THE GUIDELINES ESTABLISHED UNDER SUBSECTION (A) OF THIS 4 SECTION SHALL BE CONSISTENT WITH THE REQUIREMENTS OF THIS SUBTITLE.

5 (D) THE SECRETARY MAY POST ON THE DEPARTMENT'S WEBSITE THE 6 GUIDELINES ESTABLISHED UNDER SUBSECTION (A) OF THIS SECTION OR ANY 7 RELATED CLINICAL GUIDANCE, INCLUDING GUIDANCE ON AVAILABLE OPIOID 8 OVERDOSE REVERSAL DRUG FORMULATIONS, PRESCRIBING TEMPLATES, AND 9 STANDING ORDERS FOR THE OPIOID OVERDOSE REVERSAL DRUGS.

10 **13–3503.** 

11 (A) (1) SUBJECT TO SUBSECTION (D) OF THIS SECTION, A PRESCRIBING 12 LICENSED HEALTH CARE PROVIDER MAY CO-PRESCRIBE OR A PHARMACIST MAY 13 DISPENSE WITHOUT A PRESCRIPTION FROM A LICENSED HEALTH CARE PROVIDER 14 AN OPIOID OVERDOSE REVERSAL DRUG IF THE PRESCRIBING HEALTH CARE 15 PROVIDER OR PHARMACIST DETERMINES THAT A PATIENT IS AT A HIGH RISK OF 16 EXPERIENCING AN OPIOID OVERDOSE BECAUSE THE INDIVIDUAL IS:

- 17 (I) **PRESCRIBED OPIOIDS FOR ACUTE OR CHRONIC PAIN;** 
  - 18

**BEING TREATED FOR AN OPIOID USE DISORDER; OR** 

19

32

(III) **PRESCRIBED AN OPIOID AND A BENZODIAZEPINE.** 

20 (2) THE DEPARTMENT SHALL ENCOURAGE A PRESCRIBING 21 LICENSED HEALTH CARE PROVIDER OR PHARMACIST TO CO-PRESCRIBE OR 22 DISPENSE AN OPIOID OVERDOSE REVERSAL DRUG UNDER PARAGRAPH (1) OF THIS 23 SUBSECTION.

(3) SUBJECT TO SUBSECTION (D) OF THIS SECTION, A PRESCRIBING
LICENSED HEALTH CARE PROVIDER MAY PRESCRIBE OR A PHARMACIST MAY
DISPENSE WITHOUT A PRESCRIPTION FROM A LICENSED HEALTH CARE PROVIDER
AN OPIOID OVERDOSE REVERSAL DRUG IF THE PRESCRIBING HEALTH CARE
PROVIDER OR PHARMACIST DETERMINES THAT A PATIENT IS AT A HIGH RISK OF
WITNESSING AN OPIOID OVERDOSE BECAUSE THE INDIVIDUAL RESIDES OR SPENDS
TIME WITH AN INDIVIDUAL WHO:

31 (I) IS PRESCRIBED AN OPIOID;

**(II)** 

(II) MISUSES OPIOIDS; OR

1

(III) HAS AN OPIOID USE DISORDER.

2 (B) (1) A PRESCRIBING LICENSED HEALTH CARE PROVIDER SHALL 3 ROUTINELY ASSESS A PATIENT'S RISK OF BEING LIKELY TO EXPERIENCE OR 4 WITNESS AN OPIOID OVERDOSE.

5 (2) A PRESCRIBING LICENSED HEALTH CARE PROVIDER OR 6 PHARMACIST MAY USE INFORMATION AVAILABLE TO THE PRESCRIBING LICENSED 7 HEALTH CARE PROVIDER OR PHARMACIST TO DETERMINE A PATIENT'S RISK OF 8 BEING LIKELY TO EXPERIENCE AN OPIOID OVERDOSE, INCLUDING INFORMATION 9 FROM:

10 (I) THE MARYLAND PRESCRIPTION DRUG MONITORING 11 PROGRAM;

12

(II) THE PATIENT'S MEDICAL RECORD; AND

13(III) IF APPROPRIATE AND TO THE EXTENT ALLOWED BY LAW,14THE PATIENT'S FAMILY.

15 (C) IF THE PRESCRIBING LICENSED HEALTH CARE PROVIDER OR 16 PHARMACIST DETERMINES THAT A PATIENT IS AT RISK OF HAVING OR WITNESSING 17 AN OPIOID OVERDOSE, THE PRESCRIBING LICENSED HEALTH CARE PROVIDER OR 18 PHARMACIST SHALL:

19(1) EDUCATE THE PATIENT ON THE RISKS OF AN OPIOID OVERDOSE,20INCLUDING THAT:

(I) THE MEDICATION BEING PRESCRIBED OR DISPENSED IS
 ADDICTIVE AND MAY CAUSE RESPIRATORY DEPRESSION OR AN OVERDOSE WHEN
 COMBINED WITH OTHER DRUGS; AND

24(II)AN ANTIDOTE OR OPIOID OVERDOSE REVERSAL DRUG IS25AVAILABLE AND MAY BE PRESCRIBED OR DISPENSED WITH AN OPIOID OF 5026MORPHINE MILLIGRAM EQUIVALENTS OR HIGHER;

27 (2) OFFER TO PRESCRIBE OR DISPENSE AN OPIOID OVERDOSE 28 REVERSAL DRUG;

29 (3) ENCOURAGE THE PATIENT TO FOLLOW ANY DIRECTIONS FOR 30 USING THE DRUG BY THE FEDERAL FOOD AND DRUG ADMINISTRATION; AND 1 (4) STATE THAT TAKING AN OPIOID OVERDOSE REVERSAL DRUG IS 2 NOT A REPLACEMENT FOR CALLING 9–1–1 IN THE EVENT OF AN OVERDOSE.

3 (D) A PRESCRIBING LICENSED HEALTH CARE PROVIDER OR PHARMACIST 4 MAY NOT PRESCRIBE OR DISPENSE AN OPIOID OVERDOSE REVERSAL DRUG UNDER 5 THIS SECTION UNTIL THE PRESCRIBING LICENSED HEALTH CARE PROVIDER OR 6 PHARMACIST HAS COMPLETES 1 HOUR OF TRAINING ON THE USE OF AN OPIOID 7 OVERDOSE REVERSAL DRUG.

8 (E) THE APPROPRIATE LICENSING BOARD MAY ENFORCE THIS SECTION 9 AGAINST A PRESCRIBING LICENSED HEALTH CARE PROVIDER OR PHARMACIST.

10 (F) A PRESCRIBING LICENSED HEALTH CARE PROVIDER SHALL DOCUMENT 11 IN A PATIENT'S MEDICAL RECORD ANY SERVICES PROVIDED RELATED TO:

12 (1) CO-PRESCRIBING OR PRESCRIBING AN OPIOID OVERDOSE 13 REVERSAL DRUG; OR

14 (2) EDUCATION PROVIDED UNDER SUBSECTION (C) OF THIS SECTION.

15 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect July16 1, 2019.